Vobarilizumab
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized |
| Target | IL6R |
| Clinical data | |
| Other names | ALX0061 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1118H1757N315O364S8 |
| Molar mass | 25691.68 g·mol−1 |
Vobarilizumab (INN; development code ALX0061) is a humanized bispecific nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.